Extraordinary General Meeting held in DiaGenic ASA

14 Aug, 2012 13:51 CET

An extraordinary general meeting of DiaGenic ASA was held on 14 August
2012.

All proposals set out in the notice to the general meeting were
approved.

Please minutes from the extraordinary general meeting attached. The
minutes will also be posted on

www.newsweb.no and www.diagenic.com

Ingrid Wiik, Chairman

Telephone: +47 900 51 433

e-mail:  

Henrik Lund, Interim CEO

Telephone: +47 909 71 219

e-mail:  
About DiaGenic ASA

DiaGenic seeks to create value for patients, partners, and investors by
developing innovative and more patient friendly methods for early
detection of diseases utilizing DiaGenic's unique concept. The concept
implies that a disease evokes systemic responses in the blood unique for
the disease, and which can be measured by using blood samples.

DiaGenic is a world leader in identifying these gene expression
signatures in peripheral blood and is focused on the development of
biomarkers in the field of Alzheimer's disease and Parkinson's disease.
DiaGenic's Alzheimer's disease development program includes the CE
marked diagnostic test ADtect®, for detection of mild to moderate
Alzheimer's disease, and MCItect®which is under development for
identifying patients with very early stages of Alzheimer's disease
(prodromal AD).

DiaGenic's concept is protected through an extensive patent portfolio.
DiaGenic promotes its products and services towards leading
pharmaceutical, imaging and diagnostic companies. DiaGenic is located in
Norway and listed on the Oslo Stock Exchange. For more information
please visit: www.diagenic.